Evidence map›Paper›PMID 26536040›Full record

Trial reportPloS one2015

Assessing the HIV-1 Epidemic in Brazilian Drug Users: A Molecular Epidemiology Approach.

Monick Lindenmeyer Guimarães, Bianca Cristina Leires Marques, Neilane Bertoni, Sylvia Lopes Maia Teixeira, Mariza Gonçalves Morgado, Francisco Inácio Bastos, Brazilian Multicity Study Group on Drug Misuse

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. HIV and Substance Use in Latin America: A Scoping Review.International journal of environmental research and public health · 2022
    Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Monick Lindenmeyer GuimarãesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz- FIOCRUZ, Rio de Janeiro, Brasil.
Bianca Cristina Leires MarquesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz- FIOCRUZ, Rio de Janeiro, Brasil.
Neilane BertoniInstituto de Comunicação e Informação Científica e Tecnológica em Saúde- FIOCRUZ, Rio de Janeiro, Brasil.
Sylvia Lopes Maia TeixeiraLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz- FIOCRUZ, Rio de Janeiro, Brasil.
Mariza Gonçalves MorgadoLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz- FIOCRUZ, Rio de Janeiro, Brasil.
Francisco Inácio BastosInstituto de Comunicação e Informação Científica e Tecnológica em Saúde- FIOCRUZ, Rio de Janeiro, Brasil.
Brazilian Multicity Study Group on Drug Misuse
Fundação Oswaldo Cruz · BRInstituto de Información Científica y Tecnológica · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Person who inject illicit substances have an important role in HIV-1 blood and sexual transmission and together with person who uses heavy non-injecting drugs may have less than optimal adherence to anti-retroviral treatment and eventually could transmit resistant HIV variants. Unfortunately, molecular biology data on such key population remain fragmentary in most low and middle-income countries. The aim of the present study was to assess HIV infection rates, evaluate HIV-1 genetic diversity, drug resistance, and to identify HIV transmission clusters in heavy drug users (DUs). For this purpose, DUs were recruited in the context of a Respondent-Driven Sampling (RDS) study in different Brazilian cities during 2009. Overall, 2,812 individuals were tested for HIV, and 168 (6%) of them were positive, of which 19 (11.3%) were classified as recent seroconverters, corresponding to an estimated incidence rate of 1.58%/year (95% CI 0.92-2.43%). Neighbor joining phylogenetic trees from env and pol regions and bootscan analyses were employed to subtype the virus from132 HIV-1-infected individuals. HIV-1 subtype B was prevalent in most of the cities under analysis, followed by BF recombinants (9%-35%). HIV-1 subtype C was the most prevalent in Curitiba (46%) and Itajaí (86%) and was also detected in Brasília (9%) and Campo Grande (20%). Pure HIV-1F infections were detected in Rio de Janeiro (9%), Recife (6%), Salvador (6%) and Brasília (9%). Clusters of HIV transmission were assessed by Maximum likelihood analyses and were cross-compared with the RDS network structure. Drug resistance mutations were verified in 12.2% of DUs. Our findings reinforce the importance of the permanent HIV-1 surveillance in distinct Brazilian cities due to viral resistance and increasing subtype heterogeneity all over Brazil, with relevant implications in terms of treatment monitoring, prophylaxis and vaccine development.

Indexed as

AdolescentAdultAnti-Retroviral AgentsBrazilDrug Resistance, Viralenv Gene Products, Human Immunodeficiency VirusFemaleHIV-1HIV InfectionsHumansMalepol Gene Products, Human Immunodeficiency VirusPrevalenceSubstance Abuse, IntravenousAnti-Retroviral Agentsenv Gene Products, Human Immunodeficiency Viruspol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID26536040
PMCPMC4633026
OpenAlexW2144164162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.